Financial Review: Aadi Bioscience (NASDAQ:AADI) versus Immune Therapeutics (OTCMKTS:IMUN)

Valuation and Earnings

This table compares Aadi Bioscience and Immune Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07 million	3.54	-$65.76 million	($2.35)	-1.53
Immune Therapeutics	N/A	N/A	-$3.54 million	N/A	N/A

Immune Therapeutics has lower revenue, but higher earnings than Aadi Bioscience.

Profitability

This table compares Aadi Bioscience and Immune Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Immune Therapeutics	N/A	N/A	-544.75%

Insider and Institutional Ownership

52.1% of Aadi Bioscience shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 50.6% of Immune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Immune Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About Immune Therapeutics

Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.